Intech Investment Management LLC Invests $374,000 in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Intech Investment Management LLC acquired a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 9,677 shares of the specialty pharmaceutical company’s stock, valued at approximately $374,000.

Several other hedge funds also recently bought and sold shares of COLL. Pacer Advisors Inc. grew its stake in Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock valued at $109,749,000 after acquiring an additional 821,541 shares in the last quarter. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 27.2% during the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after acquiring an additional 499,473 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock valued at $11,661,000 after acquiring an additional 291,286 shares in the last quarter. Victory Capital Management Inc. grew its stake in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after acquiring an additional 215,874 shares in the last quarter. Finally, Emerald Advisers LLC grew its stake in Collegium Pharmaceutical by 27.2% during the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares in the last quarter.

Insider Transactions at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. This represents a 13.81 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This represents a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Trading Down 2.1 %

Shares of COLL opened at $30.66 on Wednesday. The firm has a market cap of $988.79 million, a price-to-earnings ratio of 13.22 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a fifty-two week low of $25.21 and a fifty-two week high of $42.29. The firm has a 50 day moving average price of $34.66 and a 200-day moving average price of $34.59.

Analyst Upgrades and Downgrades

COLL has been the subject of several research analyst reports. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Truist Financial lifted their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.